In colon cancer, immunohistochemical assessment of CD3+ T cells and CD8+ T cells in the tumor microenvironment has been shown to more accurately predict patient outcome than traditional UICC staging and its utility as an adjunct to traditional UICC staging has been proposed [51]. The gene discussed is CD8A; the disease is neoplasm.